Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06333860
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-21
Brief Title:
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment Works Throughout the Whole Body
Sponsor:
AbbVie
Organization:
AbbVie
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-10
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-21
First Submit QC Date:
March 21 2024
Study First Post Date:
2024-03-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-22
Last Update Post Date:
2024-07-15
Last Update Post Date Type:
ESTIMATED